AIM ImmunoTech completes dosing in Phase 2 pancreatic cancer trial, expects results in 2027

AIM ImmunoTech announced that dosing is finished for its Phase 2 DURIPANC study of Ampligen combined with AstraZeneca’s Imfinzi in metastatic pancreatic cancer. The company plans primary‑endpoint analysis in December 2026 and expects topline clinical‑benefit data in the first quarter of 2027, with additional survival data later that year. For the quarter ended September 30 2026, AIM reported cash of $6.9 million, R&D expenses of $846 thousand and a net loss of $3.1 million. The firm also secured new patents for Ampligen combinations and repaid a February 2024 promissory note.

The upcoming Q1 2027 topline data could materially affect AIM’s valuation if the trial shows benefit, according to the company’s press release. The $6.9 million cash balance provides runway to fund the trial and related activities through the expected result dates.

  • 1AIM completed dosing in its Phase 2 DURIPANC trial of Ampligen plus Imfinzi.
  • 2Primary endpoint analysis is scheduled for December 2026.
  • 3Topline clinical‑benefit results are anticipated in Q1 2027.
  • 4Cash and marketable securities were approximately $6.9 million for Q3 2026.
  • 5Research and development expenses were approximately $846 thousand for Q3 2026.
  • 6Net loss was approximately $3.1 million for Q3 2026.

Sources